Nanjing Leads Biolabs Co Ltd
HKSE: 9887.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Xiaoqiang Kang
- Employees
- 195
- Headquarters
- Nanjing, China
- IPO year
- 2025
- Market cap
- HK$16.0B
- Website
- https://www.leadsbiolabs.com
Loading 9887…
Loading profile data…Frequently asked questions about 9887
What does Nanjing Leads Biolabs Co Ltd (9887.HK) do?
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company's lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine...
Where does 9887.HK trade?
Nanjing Leads Biolabs Co Ltd (9887.HK) trades on the Hong Kong Stock Exchange.
What sector is 9887.HK in?
Nanjing Leads Biolabs Co Ltd (9887.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Nanjing Leads Biolabs Co Ltd?
Xiaoqiang Kang is the chief executive officer of Nanjing Leads Biolabs Co Ltd (9887.HK).
Where is Nanjing Leads Biolabs Co Ltd headquartered?
Nanjing Leads Biolabs Co Ltd is headquartered in China.
Does 9887.HK pay a dividend?
Nanjing Leads Biolabs Co Ltd (9887.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 9887.HK go public?
Nanjing Leads Biolabs Co Ltd (9887.HK) completed its initial public offering in 2025.